Repeated administration of an acetylcholinesterase inhibitor attenuates nicotine taking in rats and smoking behavior in human smokers

Translational Psychiatry

Volumn 6, Issue 1, 2016, Pages

  Ashare, R L ^a   Kimmey, B A ^a   Rupprecht, L E ^a   Bowers, M E ^a   Hayes, M R ^a,b   Schmidt, H D ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA SCHOOL OF NURSING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; INDAN DERIVATIVE; NICOTINE; PIPERIDINE DERIVATIVE;

ADOLESCENT; ADULT; ANIMAL; FEMALE; HUMAN; MALE; MIDDLE AGED; PREVENTION AND CONTROL; RAT; SMOKING; YOUNG ADULT;

ADOLESCENT; ADULT; ANIMALS; CHOLINESTERASE INHIBITORS; FEMALE; GALANTAMINE; HUMANS; INDANS; MALE; MIDDLE AGED; NICOTINE; PIPERIDINES; RATS; SMOKING; YOUNG ADULT;

EID: 84989355906     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/TP.2015.209     Document Type: Article

References (66)

1. Rostron B. Smoking-attributable mortality by cause in the United States: revising the CDC's data and estimates. Nicotine Tob Res 2013; 15: 238–246.
2. Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA 2014; 311: 193–194.
3. Schnoll RA, Lerman C. Current and emerging pharmacotherapies for treating tobacco dependence. Expert Opin Emerg Drugs 2006; 11: 429–444.
4. Chong CR, Sullivan DJ. New uses for old drugs. Nature 2007; 448: 645–646.
5. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev 2006; CD005593.
6. Sofuoglu M, DeVito EE, Waters AJ, Carroll KM. Cognitive enhancement as a treatment for drug addictions. Neuropharmacology 2013; 64: 452–463.
7. Ashare RL, Schmidt HD. Optimizing treatments for nicotine dependence by increasing cognitive performance during withdrawal. Expert Opin Drug Discov 2014; 9: 579–594.
8. Harvey AL. The pharmacology of galanthamine and its analogues. Pharmacol Ther 1995; 68: 113–128.
9. Kosasa T, Kuriya Y, Matsui K, Yamanishi Y. Inhibitory effects of donepezil hydro-chloride (E2020) on cholinesterase activity in brain and peripheral tissues of young and aged rats. Eur J Pharmacol 1999; 386: 7–13.
10. Hopkins TJ, Rupprecht LE, Hayes MR, Blendy JA, Schmidt HD. Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats. Neuropsychopharmacology 2012; 37: 2310–2321.
11. Kimmey BA, Rupprecht LE, Hayes MR, Schmidt HD. Donepezil, an acet-ylcholinesterase inhibitor, attenuates nicotine self-administration and reinstatement of nicotine seeking in rats. Addict Biol 2012; 19: 539–551.
12. De la Garza R 2nd, Yoon JH. Evaluation of the effects of rivastigmine on cigarette smoking by methamphetamine-dependent volunteers. Prog Neuropsycho-pharmacol Biol Psychiatry 2011; 35: 1827–1830.
13. Diehl A, Nakovics H, Croissant B, Smolka MN, Batra A, Mann K. Galantamine reduces smoking in alcohol-dependent patients: a randomized, placebo-controlled trial. Int J Clin Pharmacol Ther 2006; 44: 614–622.
14. Diehl A, Nakovics H, Mutschler J, Hermann D, Kiefer F. Rivastigmine reduces tobacco craving in alcohol-dependent smokers. Pharmacopsychiatry 2009; 42: 89–94.
15. Kelly DL, McMahon RP, Weiner E, Boggs DL, Dickinson D, Conley RR et al. Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia. Schizophr Res 2008; 103: 161–168.
16. Ashare RL, Ray R, Lerman C, Strasser AA. Cognitive effects of the acet-ylcholinesterase inhibitor, donepezil, in healthy, non-treatment seeking smokers: a pilot feasibility study. Drug Alcohol Depend 2012; 126: 263–267.
17. Sofuoglu M, Herman AI, Li Y, Waters AJ. Galantamine attenuates some of the subjective effects of intravenous nicotine and improves performance on a Go No-Go task in abstinent cigarette smokers: a preliminary report. Psychopharma-cology (Berl) 2012; 224: 413–420.
18. Lerman C, LeSage MG, Perkins KA, O'Malley SS, Siegel SJ, Benowitz NL et al. Translational research in medication development for nicotine dependence. Nat Rev Drug Discov 2007; 6: 746–762.
19. Le Foll B, Pushparaj A, Pryslawsky Y, Forget B, Vemuri K, Makriyannis A et al. Translational strategies for therapeutic development in nicotine addiction: rethinking the conventional bench to bedside approach. Prog Neuropsycho-pharmacol Biol Psychiatry 2014; 52: 86–93.
20. Farlow MR, Salloway S, Tariot PN, Yardley J, Moline ML, Wang Q et al. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: a 24-week, randomized, double-blind study. Clin Ther 2010; 32: 1234–1251.
21. Dunbar F, Zhu Y, Brashear HR. Post hoc comparison of daily rates of nausea and vomiting with once-and twice-daily galantamine from a double-blind, placebo-controlled, parallel-group, 6-month study. Clin Ther 2006; 28: 365–372.
22. Mitchell D, Wells C, Hoch N, Lind K, Woods SC, Mitchell LK. Poison induced pica in rats. Physiol Behav 1976; 17: 691–697.
23. Lee AM, Arreola AC, Kimmey BA, Schmidt HD. Administration of the nicotinic acetylcholine receptor agonists ABT-089 and ABT-107 attenuates the reinstatement of nicotine-seeking behavior in rats. Behav Brain Res 2014; 274: 168–175.
24. Levin ED, Johnson JE, Slade S, Wells C, Cauley M, Petro A et al. Lorcaserin, a 5-HT2C agonist, decreases nicotine self-administration in female rats. J Pharmacol Exp Ther 2011; 338: 890–896.
25. Levin ED, Slade S, Wells C, Pruitt M, Cousins V, Cauley M et al. Histamine H(1) antagonist treatment with pyrilamine reduces nicotine self-administration in rats. Eur J Pharmacol 2011; 650: 256–260.
26. Hernandez CM, Gearhart DA, Parikh V, Hohnadel EJ, Davis LW, Middlemore ML et al. Comparison of galantamine and donepezil for effects on nerve growth factor, cholinergic markers, and memory performance in aged rats. J Pharmacol Exp Ther 2006; 316: 679–694.
27. Sharp BM, Yatsula M, Fu Y. Effects of galantamine, a nicotinic allosteric poten-tiating ligand, on nicotine-induced catecholamine release in hippocampus and nucleus accumbens of rats. J Pharmacol Exp Ther 2004; 309: 1116–1123.
28. Geerts H, Guillaumat PO, Grantham C, Bode W, Anciaux K, Sachak S. Brain levels and acetylcholinesterase inhibition with galantamine and donepezil in rats, mice, and rabbits. Brain Res 2005; 1033: 186–193.
29. Giorgetti M, Gibbons JA, Bernales S, Alfaro IE, Drieu La Rochelle C, Cremers T et al. Cognition-enhancing properties of Dimebon in a rat novel object recognition task are unlikely to be associated with acetylcholinesterase inhibition or N-methyl-D-aspartate receptor antagonism. J Pharmacol Exp Ther 2010; 333: 748–757.
30. Brown R, Burgess E, Sales S, Whiteley J. Reliability and validity of a smoking timeline follow-back interview. Psychol Addict Behav 1998; 12: 101–112.
31. Westman EC, Levin ED, Rose JE. Smoking while wearing the nicotine patch-is smoking satisfying or harmful. Clin Res 1992; 40: A871–A871.
32. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991; 86: 1119–1127.
33. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res 2001; 3: 7–16.
34. Hughes JR, Hatsukami D. Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry 1986; 43: 289–294.
35. Hughes JR. Effects of abstinence from tobacco: etiology, animal models, epide-miology, and significance—a subjective review. Nicotine Tob Res 2007; 9:329–339.
36. Watson D, Clark L, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. JPersSocPsychol1988; 54: 1063–1070.
37. Scharre DW, Shiovitz T, Zhu Y, Amatniek J. One-week dose titration of extended release galantamine in patients with Alzheimer's disease. Alzheimers Dement 2008; 4: 30–37.
38. Liu X. Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration. Psychopharmacology 2013; 230: 203–213.
39. Kimmey BA, Rupprecht LE, Hayes MR, Schmidt HD. Donepezil, an acet-ylcholinesterase inhibitor, attenuates nicotine self‐administration and reinstatement of nicotine seeking in rats. Addict Biol 2014; 19: 539–551.
40. Cropsey KL, Jackson DO, Hale GJ, Carpenter MJ, Stitzer ML. Impact of self-initiated pre-quit smoking reduction on cessation rates: results of a clinical trial of smoking cessation among female prisoners. Addict Behav 2011; 36: 73–78.
41. Hajek P, McRobbie HJ, Myers KE, Stapleton J, Dhanji AR. Use of varenicline for 4 weeks before quitting smoking: decrease in ad lib smoking and increase in smoking cessation rates. Arch Intern Med 2011; 171: 770–777.
42. Carpenter MJ, Hughes JR, Solomon LJ, Callas PW. Both smoking reduction with nicotine replacement therapy and motivational advice increase future cessation among smokers unmotivated to quit. J Consult Clin Psychol 2004; 72: 371–381.
43. Goh CW, Aw CC, Lee JH, Chen CP, Browne ER. Pharmacokinetic and pharmaco-dynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young Lister hooded rats. Drug Metab Dispos 2011; 39: 402–411.
44. Maelicke A, Albuquerque EX. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease. Eur J Pharmacol 2000; 393: 165–170.
45. Samochocki M, Hoffle A, Fehrenbacher A, Jostock R, Ludwig J, Christner C et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003; 305: 1024–1036.
46. Tuesta LM, Fowler CD, Kenny PJ. Recent advances in understanding nicotinic receptor signaling mechanisms that regulate drug self-administration behavior. Biochem Pharmacol 2011; 82: 984–995.
47. De Biasi M, Dani JA. Reward, addiction, withdrawal to nicotine. Annu Rev Neurosci 2011; 34: 105–130.
48. Le Foll B, Goldberg SR. Effects of nicotine in experimental animals and humans: an update on addictive properties. Handb Exp Pharmacol 2009; 192: 335–367.
49. Giarola A, Auber A, Chiamulera C. Acetylcholinesterase inhibitors partially generalize to nicotine discriminative stimulus effect in rats. Behav Pharmacol 2011; 22: 1–6.
50. Shoaib M, Zubaran C, Stolerman IP. Antagonism of stimulus properties of nicotine by dihydro-beta-erythroidine (DHbetaE) in rats. Psychopharmacology (Berl) 2000; 149: 140–146.
51. Zaniewska M, McCreary AC, Przegalinski E, Filip M. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. Eur J Pharmacol 2006; 540: 96–106.
52. Mohler EG, Franklin SR, Rueter LE. Discriminative-stimulus effects of NS9283, a nicotinic α4β2* positive allosteric modulator, in nicotine-discriminating rats. Psychopharmacology (Berl) 2014; 231: 67–74.
53. Rollema H, Chambers LK, Coe JW, Glowa J, Hurst RS, Lebel LA et al. Pharmacological profile of the α4β2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology 2007; 52: 985–994.
54. Smith JW, Mogg A, Tafi E, Peacey E, Pullar IA, Szekeres P et al. Ligands selective for α4β2 but not α3β4 or α7 nicotinic receptors generalise to the nicotine discriminative stimulus in the rat. Psychopharmacology (Berl) 2007; 190: 157–170.
55. O'Connor EC, Parker D, Rollema H, Mead AN. The α4β2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psycho-pharmacology (Berl) 2010; 208: 365–376.
56. George O, Lloyd A, Carroll FI, Damaj MI, Koob GF. Varenicline blocks nicotine intake in rats with extended access to nicotine self-administration. Psycho-pharmacology (Berl) 2011; 213: 715–722.
57. Shiffman S, Kirchner TR. Cigarette-by-cigarette satisfaction during ad libitum smoking. J Abnorm Psychol 2009; 118: 348–359.
58. Strong DR, Leventhal AM, Evatt DP, Haber S, Greenberg BD, Abrams D et al. Positive reactions to tobacco predict relapse after cessation. J Abnorm Psychol 2011; 120: 999–1005.
59. Sandberg A, Skold CM, Grunewald J, Eklund A, Wheelock AM. Assessing recent smoking status by measuring exhaled carbon monoxide levels. PLoS One 2011; 6: e28864.
60. Aronson S, Van Baelen B, Kavanagh S, Schwalen S. Optimal dosing of galantamine in patients with mild or moderate Alzheimer's disease: post hoc analysis of a randomized, double-blind, placebo-controlled trial. Drugs Aging 2009; 26: 231–239.
61. Wilkinson DS, Gould TJ. The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice. Behav Brain Res 2011; 223: 53–57.
62. Poole RL, Connor DA, Gould TJ. Donepezil reverses nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 J mice. Behav Neurosci 2014; 128: 588–593.
63. Loughead J, Wileyto EP, Ruparel K, Falcone M, Hopson R, Gur R et al. Working memory-related neural activity predicts future smoking relapse. Neuropsycho-pharmacology 2015; 40: 1311–1320.
64. Patterson F, Jepson C, Loughead J, Perkins K, Strasser A, Siegel S et al. Working memory deficits predict short-term smoking resumption following brief absti-nence. Drug Alcohol Depend 2010; 106: 61–64.
65. Perkins KA, Lerman C, Fonte CA, Mercincavage M, Stitzer ML, Chengappa KN et al. Cross-validation of a new procedure for early screening of smoking cessation medications in humans. Clin Pharmacol Ther 2010; 88: 109–114.
66. Perkins KA, Lerman C, Karelitz JL, Jao NC, Chengappa KN, Sparks GM. Sensitivity and specificity of a procedure for early human screening of novel smoking cessation medications. Addiction 2013; 108: 1962–1968.